1,151 results on '"Cholinesterase Inhibitors adverse effects"'
Search Results
2. Donepezil as a safe alternative treatment after maculo-papular eruption related to rivastigmine in Lewy body disease: a case report and pharmacovigilance data.
- Author
-
Chouchana M, Pinel S, Colboc H, Soria A, Buard G, Delage C, Bloch V, and Lilamand M
- Subjects
- Humans, Male, Aged, Female, Aged, 80 and over, Drug Eruptions etiology, Treatment Outcome, Donepezil therapeutic use, Donepezil adverse effects, Rivastigmine therapeutic use, Rivastigmine adverse effects, Pharmacovigilance, Lewy Body Disease drug therapy, Cholinesterase Inhibitors adverse effects, Cholinesterase Inhibitors therapeutic use
- Published
- 2024
- Full Text
- View/download PDF
3. Re: Shahim et al., 2024 "Cholinesterase inhibitors are associated with reduced mortality in patients with Alzheimer's disease and previous myocardial infarction".
- Author
-
Tamborska AA, Bray CF, and Kurth T
- Subjects
- Humans, Treatment Outcome, Risk Assessment, Risk Factors, Alzheimer Disease mortality, Alzheimer Disease drug therapy, Alzheimer Disease diagnosis, Myocardial Infarction mortality, Myocardial Infarction drug therapy, Cholinesterase Inhibitors therapeutic use, Cholinesterase Inhibitors adverse effects
- Published
- 2024
- Full Text
- View/download PDF
4. Reply to 'Cholinesterase inhibitors are associated with reduced mortality in patients with Alzheimer's disease and previous myocardial infarction'.
- Author
-
Shahim B, Xu H, and Eriksdotter M
- Subjects
- Humans, Alzheimer Disease mortality, Alzheimer Disease drug therapy, Alzheimer Disease diagnosis, Myocardial Infarction mortality, Myocardial Infarction drug therapy, Cholinesterase Inhibitors therapeutic use, Cholinesterase Inhibitors adverse effects
- Published
- 2024
- Full Text
- View/download PDF
5. Proarrhythmic major adverse cardiac events with donepezil: A systematic review with meta-analysis.
- Author
-
Nham T, Garcia MC, Tsang KJ, Silva JM, Schneider T, Deng J, Lohit S, Mbuagbaw L, and Holbrook A
- Subjects
- Humans, Randomized Controlled Trials as Topic, Aged, Arrhythmias, Cardiac chemically induced, Arrhythmias, Cardiac epidemiology, Donepezil therapeutic use, Donepezil adverse effects, Cholinesterase Inhibitors therapeutic use, Cholinesterase Inhibitors adverse effects, Alzheimer Disease drug therapy
- Abstract
Background: Cholinesterase inhibitors (ChEIs) are regularly used in Alzheimer's disease. Of the three ChEIs approved for dementia, donepezil is among the most prescribed drugs in the United States with nearly 6 million prescriptions in 2020; however, it is classified as a "known risk" QT interval-prolonging medication (QTPmed). Given this claim is derived from observational data including single case reports, we aimed to evaluate high-quality literature on the frequency and nature of proarrhythmic major adverse cardiac events (MACE) associated with donepezil., Methods: We searched Medline, Embase, International Pharmaceutical Abstracts, and Cochrane Central from 1996 onwards for randomized controlled trials (RCTs) involving patients age ≥18 years comparing donepezil to placebo. The MACE composite included mortality, sudden cardiac death, non-fatal cardiac arrest, Torsades de pointes, ventricular tachyarrhythmia, seizure or syncope. Random-effects meta-analyses were performed with a treatment-arm continuity correction for single and double zero event studies., Results: Sixty RCTs (n = 12,463) were included. Twenty-five of 60 trials (n = 5886) investigated participants with Alzheimer's disease and 33 trials monitored electrocardiogram data. The mean follow-up duration was 31 weeks (SD = 36). Mortality was the most commonly reported MACE (252/331, 75.8% events), the remainder were syncope or seizures, with no arrhythmia events. There was no increased risk of MACE with exposure to donepezil compared to placebo (risk ratio [RR] 1.08, 95% CI 0.88-1.33, I
2 = 0%) and this was consistent in the subgroup analysis of trials including participants with cardiovascular morbidities (RR 1.14, 95% CI 0.88-1.47). Subgroup analysis suggested a trend toward more events with donepezil with follow-up ≥52 weeks (RR: 1.32, 0.98-1.79)., Conclusions: This systematic review with meta-analysis found donepezil may not be arrhythmogenic. Donepezil was not associated with mortality, ventricular arrhythmias, seizure or syncope, although longer durations of therapy need more study. Further research to clarify actual clinical outcomes related to QTPmed is important to inform prescribing practices., (© 2024 The Authors. Journal of the American Geriatrics Society published by Wiley Periodicals LLC on behalf of The American Geriatrics Society.)- Published
- 2024
- Full Text
- View/download PDF
6. Postoperative Gastrointestinal Dysfunction After Neuromuscular Blockade Reversal With Sugammadex Versus Cholinesterase Inhibitors in Patients Undergoing Gastrointestinal Surgery: A Systematic Review and Meta-Analysis.
- Author
-
Sharma S, McKechnie T, Talwar G, Patel J, Heimann L, Doumouras A, Hong D, and Eskicioglu C
- Subjects
- Humans, Gastrointestinal Diseases, Length of Stay, Cholinesterase Inhibitors therapeutic use, Cholinesterase Inhibitors adverse effects, Digestive System Surgical Procedures adverse effects, Neuromuscular Blockade adverse effects, Neuromuscular Blockade methods, Postoperative Complications, Sugammadex administration & dosage, Sugammadex therapeutic use
- Abstract
Background: Postoperative gastrointestinal dysfunction (POGD) commonly occurs following gastrointestinal (GI) surgery and is associated with specific anesthetic agents. Cholinesterase inhibitors employed for reversing neuromuscular blockade have been implicated in development of POGD. Sugammadex, a novel reversal agent, is linked with reduced POGD. However, there is a lack of comprehensive comparative review between these agents regarding their impact on POGD following GI surgery. This study aims to systematically review the effects of sugammadex on POGD compared to cholinesterase inhibitors following GI surgery., Methods: MEDLINE, EMBASE, and CENTRAL were searched as of July 2022 to identify articles comparing sugammadex with cholinesterase inhibitors in patients undergoing gastrointestinal surgery, specifically in relation to POGD. Secondary endpoints included length of hospital stay, readmission rates, pulmonary complications, and postoperative morbidity., Results: From 198 citations, 2 randomized controlled trials (RCTs) and 3 retrospective cohorts with 717 patients receiving sugammadex and 812 patients receiving cholinesterase inhibitors were included. Significantly lower rates of prolonged postoperative ileus (OR .44, 95% CI .25-.77, P < .05, I
2 = 56%, low certainty evidence) was observed with sugammadex. No significant difference in any other outcome was observed. Narrative review of readmission data demonstrated no significant difference., Conclusion: The use of sugammadex following gastrointestinal surgery is associated with significantly lower rates of prolonged postoperative ileus compared to cholinesterase inhibitors. However, these do not translate into a significant reduction in length of stay, morbidity, or postoperative nausea and vomiting. Results are limited by the numer of studies included and missing data, more robust RCTs are needed before recommendations can be made., Competing Interests: Declaration of Conflicting InterestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.- Published
- 2024
- Full Text
- View/download PDF
7. Pyridostigmine to Reduce the duration of postoperative Ileus after Colorectal surgery (PyRICo-RCT): randomized clinical trial.
- Author
-
Traeger L, Bedrikovetski S, Fitzsimmons T, Nguyen TM, Moore JW, Lewis M, and Sammour T
- Subjects
- Humans, Male, Female, Double-Blind Method, Middle Aged, Aged, Length of Stay, Adult, Treatment Outcome, Ileus prevention & control, Ileus etiology, Postoperative Complications prevention & control, Cholinesterase Inhibitors administration & dosage, Cholinesterase Inhibitors adverse effects, Cholinesterase Inhibitors therapeutic use, Pyridostigmine Bromide administration & dosage, Pyridostigmine Bromide therapeutic use
- Abstract
Background: Postoperative ileus, driven by the cholinergic anti-inflammatory pathway, is the most common complication in patients undergoing colorectal surgery. By inhibiting acetylcholinesterase, pyridostigmine can potentially modulate the cholinergic anti-inflammatory pathway and accelerate gastrointestinal recovery. This study aimed to assess the efficacy of pyridostigmine in improving gastrointestinal recovery after colorectal surgery., Methods: This double-blinded RCT enrolled adult patients undergoing elective colorectal surgery at two hospitals in South Australia. Patients were randomized to 60 mg oral pyridostigmine or placebo twice daily starting 6 h after surgery until the first passage of stool. The primary outcome was GI-2, a validated composite measure of time to first stool and tolerance of oral diet. Secondary outcomes included incidence of postoperative ileus (defined as GI-2 greater than 4 days), duration of hospital stay, and 30-day complications, evaluated by intention-to-treat univariate analysis., Results: Of 130 patients recruited (mean(s.d.) age 58.4(16.4) years; 73 men, 56%), 65 were allocated to each arm. The median GI-2 was 1 day shorter with pyridostigmine compared with placebo (2 (i.q.r. 1-3) versus 3 (2-4) days; P = 0.015). However, there were no significant differences in postoperative ileus (17.2 versus 21.5%; P = 0.532) or duration of hospital stay (median 5 (i.q.r. 4-8.75) versus 5 (4-7.5) days; P = 0.921). Similarly, there were no significant differences in overall complications, anastomotic leak, cardiac complications, or patient-reported side effects., Conclusion: Pyridostigmine resulted in a quicker return of GI-2 and was well tolerated. Larger multicentre studies are required to determine the optimal dosing and evaluate the impact of pyridostigmine in different surgical settings. Registration number: ACTRN12621000530820 (https://anzctr.org.au)., (© The Author(s) 2024. Published by Oxford University Press on behalf of BJS Foundation Ltd. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.)
- Published
- 2024
- Full Text
- View/download PDF
8. Cumulative Anticholinergic Burden and its Predictors among Older Adults with Alzheimer's Disease Initiating Cholinesterase Inhibitors.
- Author
-
Talwar A, Chatterjee S, Sherer J, Abughosh S, Johnson M, and Aparasu RR
- Subjects
- Humans, Female, Aged, United States, Male, Cholinergic Antagonists adverse effects, Retrospective Studies, Longitudinal Studies, Medicare, Cholinesterase Inhibitors adverse effects, Alzheimer Disease drug therapy, Alzheimer Disease psychology
- Abstract
Background: Cumulative anticholinergic burden refers to the cumulative effect of multiple medications with anticholinergic properties. However, concomitant use of cholinesterase inhibitors (ChEIs) and anticholinergic burden can nullify the benefit of the treatment and worsen Alzheimer's disease (AD). A literature gap exists regarding the extent of the cumulative anticholinergic burden and associated risk factors in AD. Therefore, this study evaluated the prevalence and predictors of cumulative anticholinergic burden among patients with AD initiating ChEIs., Methods: A retrospective longitudinal cohort study was conducted using the Medicare claims data involving parts A, B, and D from 2013 to 2017. The study sample included older adults (65 years and older) diagnosed with AD and initiating ChEIs (donepezil, rivastigmine, or galantamine). The cumulative anticholinergic burden was calculated based on the Anticholinergic Cognitive Burden scale and patient-specific dosing using the defined daily dose over the 1 year follow-up period after ChEI initiation. Incremental anticholinergic burden levels were dichotomized into moderate-high (sum of standardized daily anticholinergic exposure over a year (TSDD) score ≥ 90) versus low-no (score 0-89). The Andersen Behavioral Model was used as the conceptual framework for selecting the predictors under the predisposing, enabling, and need categories. A multivariable logistic regression model was used to evaluate the predictors of high-moderate versus low-no cumulative anticholinergic burden. A multinomial logistic regression model was also used to determine the factors associated with patients having moderate and high burdens compared to low/no burdens., Results: The study included 222,064 older adults with AD with incident ChEI use (mean age 82.24 ± 7.29, 68.9% females, 83.6% White). Overall, 80.48% had some anticholinergic burden during the follow-up, with 36.26% patients with moderate (TSDD scores 90-499), followed by 24.76% high (TSDD score > 500), and 19.46% with low (TSDD score 1-89) burden categories. Predisposing factors such as age; African American, Asian, or Hispanic race; and need factors included comorbidities such as dyslipidemia, syncope, delirium, fracture, pneumonia, epilepsy, and claims-based frailty index were less likely to be associated with the moderate-high anticholinergic burden. The factors that increased the odds of moderate-high burden were predisposing factors such as female sex; enabling factors such as dual eligibility and diagnosis year; and need factors such as baseline burden, behavioral and psychological symptoms of dementia, depression, insomnia, urinary incontinence, irritable bowel syndrome, anxiety, muscle spasm, gastroesophageal reflux disease, heart failure, and dysrhythmia. Most of these findings remained consistent with multinomial logistic regression. CONCLUSION: Four out of five older adults with AD had some level of anticholinergic burden, with over 60% having moderate-high anticholinergic burden. Several predisposing, enabling, and need factors were associated with the cumulative anticholinergic burden. The study findings suggest a critical need to minimize the cumulative anticholinergic burden to improve AD care., (© 2024. The Author(s), under exclusive licence to Springer Nature Switzerland AG.)
- Published
- 2024
- Full Text
- View/download PDF
9. Adverse Drug Event Profile Associated with Anti-dementia Drugs: Analysis of a Spontaneous Reporting Database.
- Author
-
Kose E, Yamamoto T, Tate N, Ando A, Enomoto H, and Yasuno N
- Subjects
- Humans, Donepezil adverse effects, Rivastigmine adverse effects, Galantamine adverse effects, Memantine adverse effects, Acetylcholinesterase, Piperidines, Indans adverse effects, Cholinesterase Inhibitors adverse effects, Drug-Related Side Effects and Adverse Reactions epidemiology
- Abstract
Adverse drug events (ADEs) rates associated with anti-dementia acetylcholinesterase inhibitors are estimated to be 5%-20% and show a wide range of symptoms. No report has examined whether there is a difference in the anti-dementia drugs' ADEs profile. This study aimed to establish whether anti-dementia drugs' ADEs profile differed. Data was based on the Japanese Adverse Drug Event Report (JADER) database. The reporting odds ratios (RORs) was used to analyze data for ADEs from April 2004-October 2021. The target drugs were donepezil, rivastigmine, galantamine, and memantine. The top ten most frequently occurring adverse events were selected. The association between the RORs and antidementia drug ADEs was evaluated, and compared the distribution rate of expression age related to ADEs and each ADEs' timing of onset due to anti-dementia drugs. The primary outcome was RORs. Secondary outcome were expression age and time-to-onset of ADE associated with anti-dementia drugs. A total of 705,294 reports were analyzed. The adverse events incidence differed. Bradycardia, loss of consciousness, falls, and syncope incidence were significantly diverse. The Kaplan-Meier curve results for the cumulative ADEs incidence showed that donepezil had the slowest onset, while galantamine, rivastigmine, and memantine had approximately the same timing of onset.
- Published
- 2023
- Full Text
- View/download PDF
10. Risk of Serious Adverse Events Associated With Individual Cholinesterase Inhibitors Use in Older Adults With Dementia: A Population-Based Cohort Study.
- Author
-
Masurkar PP, Chatterjee S, Sherer JT, Chen H, Johnson ML, and Aparasu RR
- Subjects
- Aged, Cohort Studies, Donepezil adverse effects, Female, Galantamine adverse effects, Humans, Indans therapeutic use, Male, Medicare, Phenylcarbamates adverse effects, Piperidines adverse effects, Retrospective Studies, Rivastigmine adverse effects, United States, Alzheimer Disease drug therapy, Cholinesterase Inhibitors adverse effects
- Abstract
Background and Objective: Cholinesterase inhibitors (ChEIs) are used as first-line pharmacotherapy to manage dementia. However, there are limited data regarding their relative safety. This study evaluated the risk of serious adverse events (SAEs) associated with individual ChEIs in older adults with dementia and also examined sex-based and dose-based effects on this risk., Methods: This was a retrospective cohort study using 2013-2015 US Medicare claims data involving Parts A, B, and D. Patients aged ≥ 65 years with a dementia diagnosis and incident use of the ChEIs, namely donepezil, galantamine, or rivastigmine, were included. The primary outcome of interest was SAEs defined as emergency department visits, inpatient hospitalizations, or death within 6 months of ChEI initiation. Multivariable Cox proportional hazards regression with propensity score (PS) as a covariate and inverse probability of treatment weighting generated using generalized boosted models was used to assess the risk of SAEs across individual ChEIs., Results: The study included 767,684 older adults with dementia who were incident new users of ChEIs (donepezil 79.42%, rivastigmine 17.67%, galantamine 2.91%). SAEs were observed in 15.5% of the cohort within 6 months of ChEI prescription. Cox regression model with PS as covariate found that patients prescribed rivastigmine (adjusted hazard ratio [aHR] 1.12; 95% CI 1.03-1.33) and galantamine (aHR 1.51; 95% CI 1.24-1.84) were at increased risk of SAEs compared with patients on donepezil. Stratified analyses revealed that rivastigmine was associated with an 18% increased risk for SAEs in females (aHR 1.18; 95% CI 1.06-1.31), and galantamine was associated with a 71% increased risk in males (aHR 1.71; 95% CI 1.17-2.51) compared with donepezil. High and recommended index doses of rivastigmine and galantamine were associated with an increased risk of SAEs compared with donepezil. The findings were consistent in sensitivity analyses., Conclusion: The study found that the risk of SAEs varied across individual ChEIs, with sex and dose moderating these effects. Therefore, these moderating effects should be carefully considered in personalizing dementia care., (© 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.)
- Published
- 2022
- Full Text
- View/download PDF
11. Association between long-term usage of acetylcholinesterase inhibitors and lung cancer in the elderly: a nationwide cohort study.
- Author
-
Liu CT, Yang CC, Chien WC, Chung CH, Tsai CS, Tsai YT, Lin CY, Lin YC, Chen YS, and Tzeng NS
- Subjects
- Acetylcholinesterase, Aged, Cohort Studies, Comorbidity, Galantamine adverse effects, Humans, Proportional Hazards Models, Retrospective Studies, Risk Factors, Rivastigmine adverse effects, Taiwan epidemiology, Cholinesterase Inhibitors adverse effects, Lung Neoplasms chemically induced, Lung Neoplasms drug therapy, Lung Neoplasms epidemiology
- Abstract
This retrospective cohort study aimed to evaluate the association between acetylcholinesterase inhibitors (AChEI) usage and the risk of lung cancer. Data from 116,106 new users of AChEI and 348,318, at a ratio of 1:3, matched by age, sex, and index-year, between 2000 and 2015 controls were obtained from the Taiwan Longitudinal Health Insurance Database in this cohort study. The Cox regression model was used to compare the risk of lung cancer. The adjusted hazard ratio (aHR) of lung cancer for AChEI users was 1.198 (95% confidence interval [CI] = 0.765-1.774, p = 0.167). However, the adjusted HR for patients aged ≥ 65 was adjusted to HR: 1.498 (95% CI = 1.124-1.798, p < 0.001), in contrast to the comparison groups. In addition, patients with comorbidities such as pneumonia, bronchiectasis, pneumoconiosis, pulmonary alveolar pneumonopathy, hypertension, stroke, coronary artery disease, diabetes mellitus, chronic kidney disease, depression, anxiety, smoking-related diseases, dementia, and seeking medical help from medical centers and regional hospitals, were associated with a higher risk in lung cancer. Furthermore, longer-term usage of rivastigmine (366-730 days, ≥ 731 days) and galantamine (≥ 731 days) was associated with the risk of lung cancer. AChEI increased the risk of lung cancer in the older aged patients, several comorbidities, and a longer-term usage of rivastigmine and galantamine. Therefore, physicians should estimate the risks and benefits of AChEI usage and avoid prescribing antidepressants concurrently., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
12. Massive Weight Loss From Rivastigmine Patch in an Older Patient: A Rare Case.
- Author
-
Naharci MI, Veizi BGY, Katipoglu B, Akcan E, Yoruk F, and Tasci I
- Subjects
- Administration, Cutaneous, Humans, Phenylcarbamates therapeutic use, Rivastigmine adverse effects, Transdermal Patch, Weight Loss, Alzheimer Disease drug therapy, Cholinesterase Inhibitors adverse effects
- Published
- 2022
- Full Text
- View/download PDF
13. The biological activities of butyrylcholinesterase inhibitors.
- Author
-
Zhou S and Huang G
- Subjects
- Acridines chemistry, Acridines pharmacology, Alzheimer Disease drug therapy, Butyrylcholinesterase adverse effects, Butyrylcholinesterase chemistry, Cholinesterase Inhibitors adverse effects, Cholinesterase Inhibitors chemistry, Humans, Methoxsalen analogs & derivatives, Methoxsalen chemistry, Methoxsalen pharmacology, Structure-Activity Relationship, Butyrylcholinesterase pharmacology, Cholinesterase Inhibitors pharmacology
- Abstract
Acetylcholinesterase (AChE) inhibitor is the first choice for the treatment of Alzheimer's disease (AD), but it has some defects, such as dose limitation and unsatisfactory long-term treatment effect. Recent studies have shown that butyrylcholinesterase (BuChE) inhibitors or double acetyl and butyryl cholinesterase inhibitors have better curative effects on AD, and the side effects are lower than those of specific AChE inhibitors. Dual target cholinesterase inhibitors have become a new hotspot in the research of anti-AD drugs. Herein, the synthesis and bioactivities of BuChE inhibitors were reviewed., (Copyright © 2021 The Authors. Published by Elsevier Masson SAS.. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
14. Balanced modulation of neuromuscular synaptic transmission via M1 and M2 muscarinic receptors during inhibition of cholinesterases.
- Author
-
Lenina OA and Petrov KA
- Subjects
- Animals, Cholinesterase Inhibitors administration & dosage, Cholinesterases metabolism, Diaphragm drug effects, Disease Models, Animal, Mice, Muscle Contraction drug effects, Muscle Weakness metabolism, Paraoxon administration & dosage, Pirenzepine administration & dosage, Receptor, Muscarinic M1 antagonists & inhibitors, Receptor, Muscarinic M2 antagonists & inhibitors, Signal Transduction drug effects, Treatment Outcome, Antidotes administration & dosage, Atropine administration & dosage, Cholinesterase Inhibitors adverse effects, Diamines administration & dosage, Muscarinic Antagonists administration & dosage, Muscle Weakness chemically induced, Muscle Weakness prevention & control, Paraoxon adverse effects, Parasympatholytics administration & dosage, Protective Agents administration & dosage, Receptor, Muscarinic M1 metabolism, Receptor, Muscarinic M2 metabolism, Synaptic Transmission drug effects
- Abstract
Organophosphorus (OP) compounds that inhibit acetylcholinesterase are a common cause of poisoning worldwide, resulting in several hundred thousand deaths each year. The pathways activated during OP compound poisoning via overstimulation of muscarinic acetylcholine receptors (mAChRs) play a decisive role in toxidrome. The antidotal therapy includes atropine, which is a nonspecific blocker of all mAChR subtypes. Atropine is efficient for mitigating depression in respiratory control centers but does not benefit patients with OP-induced skeletal muscle weakness. By using an ex vivo model of OP-induced muscle weakness, we studied the effects of the M1/M4 mAChR antagonist pirenzepine and the M2/M4 mAChR antagonist methoctramine on the force of mouse diaphragm muscle contraction. It was shown that weakness caused by the application of paraoxon can be significantly prevented by methoctramine (1 µM). However, neither pirenzepine (0.1 µM) nor atropine (1 µM) was able to prevent muscle weakness. Moreover, the application of pirenzepine significantly reduced the positive effect of methoctramine. Thus, balanced modulation of neuromuscular synaptic transmission via M1 and M2 mAChRs contributes to paraoxon-induced muscle weakness. It was shown that methoctramine (10 µmol/kg, i.p.) and atropine (50 µmol/kg, i.p.) were equieffective toward increasing the survival of mice poisoned with a 2xLD
50 dose of paraoxon., (© 2022. The Author(s).)- Published
- 2022
- Full Text
- View/download PDF
15. Author Response: Long-term Effects of Cholinesterase Inhibitors on Cognitive Decline and Mortality.
- Author
-
Xu H, Garcia-Ptacek S, and Eriksdotter M
- Subjects
- Humans, Indans, Cholinesterase Inhibitors adverse effects, Cognitive Dysfunction chemically induced
- Published
- 2021
- Full Text
- View/download PDF
16. Donepezil and Inappropriate Sexual Behavior in a Patient With Vascular Dementia and on Bupropion: A Case Report.
- Author
-
Haghani Tehrani P, Kohli KK, and Khafaja MH
- Subjects
- Aged, Drug Therapy, Combination, Humans, Bupropion adverse effects, Cholinesterase Inhibitors adverse effects, Dementia, Vascular drug therapy, Dementia, Vascular physiopathology, Donepezil adverse effects, Dopamine Uptake Inhibitors adverse effects, Sexual Behavior drug effects
- Published
- 2021
- Full Text
- View/download PDF
17. Acetylcholinesterase Inhibitors in Myasthenic Crisis: A Systematic Review of Observational Studies.
- Author
-
Prado MB Jr and Adiao KJ
- Subjects
- Acetylcholinesterase, Humans, Neostigmine, Plasmapheresis, Cholinesterase Inhibitors adverse effects, Myasthenia Gravis drug therapy
- Abstract
Current myasthenia gravis guidelines recommend intravenous immunoglobulin or plasmapheresis and discontinuation of pyridostigmine during myasthenic crisis. However, intravenous immunoglobulin or plasmapheresis is expensive and frequently not available in developing countries. This study aims to summarize the evidence of giving an acetylcholinesterase inhibitor in myasthenic crisis. Medline, Embase, and Cochrane databases and references were searched for observational studies that determined the use of acetylcholinesterase inhibitor in myasthenic crisis. The eligibility criteria were as follows: population, patients with myasthenic crisis, intervention (acetylcholinesterase inhibitor administration), and outcome (clinical improvement and complications). In total, 106 studies were identified, 92 through database searching (after removing duplicates) and 14 through other sources. Only eight were analyzed in the present systematic review. In five, acetylcholinesterase inhibitor was given at the start of the crisis, whereas in the other three, acetylcholinesterase inhibitor was discontinued initially and then restarted prior to extubation. Two observational analytic studies and three case reports showed improvement in different outcome measures. In the other three, improvement of outcome measures was also observed. Overall, a small proportion of patients developed cardiac arrhythmia and pneumonia after administration of acetylcholinesterase inhibitor alone, although this was not statistically different compared with those subjected to plasmapheresis. In summary, continuous intravenous infusion of pyridostigmine or neostigmine can be a substitute for intravenous immunoglobulin or plasmapheresis if these are not available during crisis; however, caution should be observed because of the aforementioned possible complications., (© 2021. Springer Science+Business Media, LLC, part of Springer Nature and Neurocritical Care Society.)
- Published
- 2021
- Full Text
- View/download PDF
18. Use of antipsychotic drugs and cholinesterase inhibitors and risk of falls and fractures: self-controlled case series.
- Author
-
Wang GH, Man KKC, Chang WH, Liao TC, and Lai EC
- Subjects
- Aged, Aged, 80 and over, Antipsychotic Agents adverse effects, Cholinesterase Inhibitors adverse effects, Databases, Factual, Female, Fractures, Bone epidemiology, Humans, Incidence, Male, Neurocognitive Disorders drug therapy, Risk Assessment, Taiwan, Accidental Falls statistics & numerical data, Antipsychotic Agents administration & dosage, Cholinesterase Inhibitors administration & dosage
- Abstract
Objective: To evaluate the association between the use of antipsychotic drugs and cholinesterase inhibitors and the risk of falls and fractures in elderly patients with major neurocognitive disorders., Design: Self-controlled case series., Setting: Taiwan's National Health Insurance Database., Participants: 15 278 adults, aged ≥65, with newly prescribed antipsychotic drugs and cholinesterase inhibitors, who had an incident fall or fracture between 2006 and 2017. Prescription records of cholinesterase inhibitors confirmed the diagnosis of major neurocognitive disorders; all use of cholinesterase inhibitors was reviewed by experts., Main Outcome Measures: Conditional Poisson regression was used to derive incidence rate ratios and 95% confidence intervals for evaluating the risk of falls and fractures for different treatment periods: use of cholinesterase inhibitors alone, antipsychotic drugs alone, and a combination of cholinesterase inhibitors and antipsychotic drugs, compared with the non-treatment period in the same individual. A 14 day pretreatment period was defined before starting the study drugs because of concerns about confounding by indication., Results: The incidence of falls and fractures per 100 person years was 8.30 (95% confidence interval 8.14 to 8.46) for the non-treatment period, 52.35 (48.46 to 56.47) for the pretreatment period, and 10.55 (9.98 to 11.14), 10.34 (9.80 to 10.89), and 9.41 (8.98 to 9.86) for use of a combination of cholinesterase inhibitors and antipsychotic drugs, antipsychotic drugs alone, and cholinesterase inhibitors alone, respectively. Compared with the non-treatment period, the highest risk of falls and fractures was during the pretreatment period (adjusted incidence rate ratio 6.17, 95% confidence interval 5.69 to 6.69), followed by treatment with the combination of cholinesterase inhibitors and antipsychotic drugs (1.35, 1.26 to 1.45), antipsychotic drugs alone (1.33, 1.24 to 1.43), and cholinesterase inhibitors alone (1.17, 1.10 to 1.24)., Conclusions: The incidence of falls and fractures was high in the pretreatment period, suggesting that factors other than the study drugs, such as underlying diseases, should be taken into consideration when evaluating the association between the risk of falls and fractures and use of cholinesterase inhibitors and antipsychotic drugs. The treatment periods were also associated with a higher risk of falls and fractures compared with the non-treatment period, although the magnitude was much lower than during the pretreatment period. Strategies for prevention and close monitoring of the risk of falls are still necessary until patients regain a more stable physical and mental state., Competing Interests: Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/disclosure-of-interest/ and declare: EC-CL reports grants from the Ministry of Science and Technology of Taiwan (107-2320-B-006-070-MY3 and 106-2320-B-006-025-MY2), outside the submitted work; KK-CM reports grants from the CW Maplethorpe Fellowship, National Institute of Health Research, UK, and the European Commission Horizon 2020 Framework, personal fees from IQVIA, and grants from Amgen and GlaxoSmithKline, outside the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work., (© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2021
- Full Text
- View/download PDF
19. Prolonged Paralysis After Electroconvulsive Therapy Due to Butyrylcholinesterase Gene Mutation.
- Author
-
Maxwell J, Boothby A, Osborne R, and Langley-DeGroot MH
- Subjects
- Aged, 80 and over, Humans, Male, Paralysis chemically induced, Apnea complications, Butyrylcholinesterase deficiency, Butyrylcholinesterase genetics, Cholinesterase Inhibitors adverse effects, Donepezil adverse effects, Electroconvulsive Therapy adverse effects, Metabolism, Inborn Errors complications, Paralysis etiology, Psychotic Disorders therapy
- Published
- 2021
- Full Text
- View/download PDF
20. Antimuscarinic Cascade Across Individual Cholinesterase Inhibitors in Older Adults with Dementia.
- Author
-
Masurkar PP, Chatterjee S, Sherer JT, and Aparasu RR
- Subjects
- Acetylcholinesterase, Aged, Humans, Muscarinic Antagonists adverse effects, Retrospective Studies, Cholinesterase Inhibitors adverse effects, Dementia drug therapy
- Abstract
Background: Acetylcholinesterase inhibitors (AChEIs) have been associated with an increased risk of starting antimuscarinic treatment to treat overactive bladder (OAB)-an example of a prescribing cascade. Limited comparative data exist regarding the prescribing cascade of antimuscarinics across individual AChEIs in older adults with dementia., Objective: This study examined the association between individual AChEI use and antimuscarinic cascade in older adults with dementia., Methods: We conducted a new user retrospective cohort study from January 2005 to December 2018 using data from the TriNetX electronic medical record database, a federated electronic medical records network in the US. The cohort included patients 65 years or older with a diagnosis of dementia using AChEIs (donepezil, galantamine, or rivastigmine). Individual AChEIs were identified with index dates from 1 January 2006 to 31 June 2018, with a 1-year washout period. The study excluded patients with any antimuscarinic use and OAB diagnosis 1 year before the AChEI index date. The primary outcome of interest was the prescription of antimuscarinics within 6 months of the AChEI index date. A Cox proportional hazard model was used to assess the association between individual incident AChEI use and antimuscarinic prescribing cascade after controlling for several covariates., Results: The study included 47,059 older adults with dementia who were incident users of AChEIs. Most of these patients were initiated with donepezil (83.1%), followed by rivastigmine (12.3%) and galantamine (4.6%). Overall, 8.16% of the study cohort had incident OAB diagnosis or antimuscarinic prescription. Antimuscarinics were initiated by 1725 (3.7%) older adults with dementia within 6 months of AChEI prescription, and cascade varied widely across individual agents-donepezil (3.9%), rivastigmine (2.6%), and galantamine (2.9%). Cox proportional hazard analyses revealed that donepezil users had an increased risk of receiving antimuscarinics (adjusted hazard ratio 1.55, 95% confidence interval 1.31-1.83) compared with rivastigmine. The findings were consistent in sensitivity analyses., Conclusion: This study found that donepezil use is more likely to lead to antimuscarinic cascade than rivastigmine. Future studies are needed to determine the potential consequences of this cascade in dementia.
- Published
- 2021
- Full Text
- View/download PDF
21. Does the application of acetylcholinesterase inhibitors in the treatment of Alzheimer's disease lead to depression?
- Author
-
Mitić M and Lazarević-Pašti T
- Subjects
- Acetylcholine metabolism, Acetylcholinesterase drug effects, Acetylcholinesterase metabolism, Alzheimer Disease psychology, Animals, Biological Products administration & dosage, Biological Products adverse effects, Biological Products pharmacology, Cholinesterase Inhibitors administration & dosage, Depression epidemiology, Drug Design, Humans, Risk, Alzheimer Disease drug therapy, Cholinesterase Inhibitors adverse effects, Depression etiology
- Abstract
Introduction : Alzheimer's disease and depression are health conditions affecting millions of people around the world. Both are strongly related to the level of the neurotransmitter acetylcholine. Since cholinergic deficit is characteristic of Alzheimer's disease, acetylcholinesterase inhibitors are applied as relevant drugs for the treatment of this disease, elevating the level of acetylcholine. On the other hand, a high level of acetylcholine is found to be associated with the symptoms of clinical depression. Areas covered : This article aims to discuss if acetylcholinesterase inhibitors used as anti-Alzheimer's drugs could be the cause of the symptoms of clinical depression often linked to this neurological disorder. Emphasis will be put on drugs currently in use and on newly investigated natural products, which can inhibit AChE activity. Expert opinion : Currently, it is not proven that the patient treated for Alzheimer's disease is prone to increased risk for depression due to the acetylcholinesterase inhibition, but there are strong indications. The level of acetylcholine is not the only factor in highly complicated diseases like AD and depression. Still, it needs to be considered isolated, keeping in mind the nature of presently available therapy, especially during a rational drug design process.
- Published
- 2021
- Full Text
- View/download PDF
22. Postoperative Pulmonary Complications' Association with Sugammadex versus Neostigmine: A Retrospective Registry Analysis.
- Author
-
Li G, Freundlich RE, Gupta RK, Hayhurst CJ, Le CH, Martin BJ, Shotwell MS, and Wanderer JP
- Subjects
- Adult, Cohort Studies, Humans, Registries, Retrospective Studies, Sugammadex adverse effects, Cholinesterase Inhibitors adverse effects, Neostigmine adverse effects
- Abstract
Background: Postoperative residual neuromuscular blockade related to nondepolarizing neuromuscular blocking agents may be associated with pulmonary complications. In this study, the authors sought to determine whether sugammadex was associated with a lower risk of postoperative pulmonary complications in comparison with neostigmine., Methods: Adult patients from the Vanderbilt University Medical Center National Surgical Quality Improvement Program database who underwent general anesthesia procedures between January 2010 and July 2019 were included in an observational cohort study. In early 2017, a wholesale switch from neostigmine to sugammadex occurred at Vanderbilt University Medical Center. The authors therefore identified all patients receiving nondepolarizing neuromuscular blockades and reversal with neostigmine or sugammadex. An inverse probability of treatment weighting propensity score analysis approach was applied to control for measured confounding. The primary outcome was postoperative pulmonary complications, determined by retrospective chart review and defined as the composite of the three postoperative respiratory occurrences: pneumonia, prolonged mechanical ventilation, and unplanned intubation., Results: Of 10,491 eligible cases, 7,800 patients received neostigmine, and 2,691 received sugammadex. A total of 575 (5.5%) patients experienced postoperative pulmonary complications (5.9% neostigmine vs. 4.2% sugammadex). Specifically, 306 (2.9%) patients had pneumonia (3.2% vs. 2.1%), 113 (1.1%) prolonged mechanical ventilation (1.1% vs. 1.1%), and 156 (1.5%) unplanned intubation (1.6% vs. 1.0%). After propensity score adjustment, the authors found a lower absolute incidence rate of postoperative pulmonary complications over time (adjusted odds ratio, 0.91 [per year]; 95% CI, 0.87 to 0.96; P < .001). No difference was observed on the odds of postoperative pulmonary complications in patients receiving sugammadex in comparison with neostigmine (adjusted odds ratio, 0.89; 95% CI, 0.65 to 1.22; P = 0.468)., Conclusions: Among 10,491 patients at a single academic tertiary care center, the authors found that switching neuromuscular blockade reversal agents was not associated with the occurrence of postoperative pulmonary complications., (Copyright © 2021, the American Society of Anesthesiologists, Inc. All Rights Reserved.)
- Published
- 2021
- Full Text
- View/download PDF
23. Analysis of electropharmacological and proarrhythmic effects of donepezil using the halothane-anesthetized intact dogs and the conscious chronic atrioventricular block ones.
- Author
-
Hagiwara-Nagasawa M, Kambayashi R, Goto A, Nunoi Y, Izumi-Nakaseko H, Chiba K, Wada T, Takei Y, Matsumoto A, and Sugiyama A
- Subjects
- Anesthetics, Inhalation, Animals, Arrhythmias, Cardiac physiopathology, Atrioventricular Block, Dogs, Female, Halothane, Heart Ventricles drug effects, Hemodynamics drug effects, Ventricular Function, Left drug effects, Arrhythmias, Cardiac chemically induced, Cholinesterase Inhibitors adverse effects, Donepezil adverse effects
- Abstract
Donepezil, an inhibitor for acetylcholinesterase used for patients with Alzheimer's disease, has been shown to inhibit I
Kr , occasionally inducing torsade de pointes. In order to analyze the causal relationship between donepezil treatment and onset of lethal arrhythmias, we initially assessed electropharmacological effects of donepezil hydrochloride of 0.01, 0.1, and 1 mg/kg, i.v. over 10 min using the halothane-anesthetized intact dogs (n = 4), possibly providing subtherapeutic to supratherapeutic plasma concentrations. Although the low or middle dose did not exert any effect, the high dose transiently increased the ventricular refractoriness along with modest prolongation of the late repolarization period, indicating potential IKr inhibitory action in vivo. Moreover, the high dose induced the positive chronotropic, inotropic, and dromotropic actions along with the pressor effect and prolongation of early repolarization period, suggesting sympathicotonic condition in the central nervous system. Next, we examined proarrhythmic effects of donepezil hydrochloride of 0.1 and 1 mg/kg, i.v. over 10 min using the conscious chronic atrioventricular block dogs (n = 4). Although the low dose hardly affected the cardiovascular variables, the high dose increased the atrial and ventricular rate without significantly altering the repolarization period, possibly reflecting sympathicotonic condition. Importantly, the high dose induced non-sustained ventricular tachycardia in half of the animals. Thus, donepezil by itself did not induce torsade de pointes in vivo, which suggests that donepezil-induced sympathicotonic condition may induce Ca2+ overload, triggering the ventricular arrhythmias, but might indirectly attenuate its IKr inhibitory action, preventing excessive repolarization delay.- Published
- 2021
- Full Text
- View/download PDF
24. Structural and Biochemical Insights into the Inhibition of Human Acetylcholinesterase by G-Series Nerve Agents and Subsequent Reactivation by HI-6.
- Author
-
McGuire JR, Bester SM, Guelta MA, Cheung J, Langley C, Winemiller MD, Bae SY, Funk V, Myslinski JM, Pegan SD, and Height JJ
- Subjects
- Acetylcholinesterase chemistry, Acetylcholinesterase isolation & purification, Cholinesterase Inhibitors chemistry, Humans, Molecular Structure, Nerve Agents chemistry, Oximes chemistry, Pyridinium Compounds chemistry, Acetylcholinesterase metabolism, Cholinesterase Inhibitors adverse effects, Nerve Agents adverse effects, Oximes adverse effects, Pyridinium Compounds adverse effects
- Abstract
The recent use of organophosphate nerve agents in Syria, Malaysia, Russia, and the United Kingdom has reinforced the potential threat of their intentional release. These agents act through their ability to inhibit human acetylcholinesterase (hAChE; E.C. 3.1.1.7), an enzyme vital for survival. The toxicity of hAChE inhibition via G-series nerve agents has been demonstrated to vary widely depending on the G-agent used. To gain insight into this issue, the structures of hAChE inhibited by tabun, sarin, cyclosarin, soman, and GP were obtained along with the inhibition kinetics for these agents. Through this information, the role of hAChE active site plasticity in agent selectivity is revealed. With reports indicating that the efficacy of reactivators can vary based on the nerve agent inhibiting hAChE, human recombinatorially expressed hAChE was utilized to define these variations for HI-6 among various G-agents. To identify the structural underpinnings of this phenomenon, the structures of tabun, sarin, and soman-inhibited hAChE in complex with HI-6 were determined. This revealed how the presence of G-agent adducts impacts reactivator access and placement within the active site. These insights will contribute toward a path of next-generation reactivators and an improved understanding of the innate issues with the current reactivators.
- Published
- 2021
- Full Text
- View/download PDF
25. Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta-analysis.
- Author
-
Battle CE, Abdul-Rahim AH, Shenkin SD, Hewitt J, and Quinn TJ
- Subjects
- Activities of Daily Living, Bias, Cholinesterase Inhibitors adverse effects, Cognition drug effects, Donepezil adverse effects, Galantamine adverse effects, Humans, Nootropic Agents administration & dosage, Nootropic Agents adverse effects, Physical Functional Performance, Placebos therapeutic use, Randomized Controlled Trials as Topic, Rivastigmine adverse effects, Cholinesterase Inhibitors administration & dosage, Dementia, Vascular drug therapy, Donepezil administration & dosage, Galantamine administration & dosage, Network Meta-Analysis, Rivastigmine administration & dosage
- Abstract
Background: Vascular cognitive impairment (VCI) describes a broad spectrum of cognitive impairments caused by cerebrovascular disease, ranging from mild cognitive impairment to dementia. There are currently no pharmacological treatments recommended for improving either cognition or function in people with VCI. Three cholinesterase inhibitors (donepezil, galantamine, and rivastigmine) are licenced for the treatment of dementia due to Alzheimer's disease. They are thought to work by compensating for reduced cholinergic neurotransmission, which is also a feature of VCI. Through pairwise comparisons with placebo and a network meta-analysis, we sought to determine whether these medications are effective in VCI and whether there are differences between them with regard to efficacy or adverse events., Objectives: (1) To assess the efficacy and safety of cholinesterase inhibitors in the treatment of adults with vascular dementia and other VCI. (2) To compare the effects of different cholinesterase inhibitors on cognition and adverse events, using network meta-analysis., Search Methods: We searched ALOIS, the Cochrane Dementia and Cognitive Improvement Group's register, MEDLINE (OvidSP), Embase (OvidSP), PsycINFO (OvidSP), CINAHL (EBSCOhost), Web of Science Core Collection (ISI Web of Science), LILACS (BIREME), ClinicalTrials.gov, and the World Health Organization International Clinical Trials Registry Platform on 19 August 2020., Selection Criteria: We included randomised controlled trials in which donepezil, galantamine, or rivastigmine was compared with placebo or in which the drugs were compared with each other in adults with vascular dementia or other VCI (excluding cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL)). We included all drug doses and routes of administration., Data Collection and Analysis: Two review authors independently identified eligible trials, extracted data, assessed risk of bias, and applied the GRADE approach to assess the certainty of the evidence. The primary outcomes were cognition, clinical global impression, function (performance of activities of daily living), and adverse events. Secondary outcomes were serious adverse events, incidence of development of new dementia, behavioural disturbance, carer burden, institutionalisation, quality of life and death. For the pairwise analyses, we pooled outcome data at similar time points using random-effects methods. We also performed a network meta-analysis using Bayesian methods., Main Results: We included eight trials (4373 participants) in the review. Three trials studied donepezil 5 mg or 10 mg daily (n= 2193); three trials studied rivastigmine at a maximum daily dose of 3 to 12 mg (n= 800); and two trials studied galantamine at a maximum daily dose of 16 to 24 mg (n= 1380). The trials included participants with possible or probable vascular dementia or cognitive impairment following stroke. Mean ages were between 72.2 and 73.9 years. All of the trials were at low or unclear risk of bias in all domains, and the evidence ranged from very low to high level of certainty. For cognition, the results showed that donepezil 5 mg improves cognition slightly, although the size of the effect is unlikely to be clinically important (mean difference (MD) -0.92 Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) points (range 0 to 70), 95% confidence interval (CI) -1.44 to -0.40; high-certainty evidence). Donepezil 10 mg (MD -2.21 ADAS-Cog points, 95% CI -3.07 to -1.35; moderate-certainty evidence) and galantamine 16 to 24 mg (MD -2.01 ADAS-Cog point, 95%CI -3.18 to -0.85; moderate-certainty evidence) probably also improve cognition, although the larger effect estimates still may not be clinically important. With low certainty, there may be little to no effect of rivastigmine 3 to 12 mg daily on cognition (MD 0.03 ADAS-Cog points, 95% CI -3.04 to 3.10; low-certainty evidence). Adverse events reported in the studies included nausea and/or vomiting, diarrhoea, dizziness, headache, and hypertension. The results showed that there was probably little to no difference between donepezil 5 mg and placebo in the number of adverse events (odds ratio (OR) 1.22, 95% CI 0.94 to 1.58; moderate-certainty evidence), but there were slightly more adverse events with donepezil 10 mg than with placebo (OR 1.95, 95% CI 1.20 to 3.15; high-certainty evidence). The effect of rivastigmine 3 to 12 mg on adverse events was very uncertain (OR 3.21, 95% CI 0.36 to 28.88; very low-certainty evidence). Galantamine 16 to 24 mg is probably associated with a slight excess of adverse events over placebo (OR 1.57, 95% CI 1.02 to 2.43; moderate-certainty evidence). In the network meta-analysis (NMA), we included cognition to represent benefit, and adverse events to represent harm. All drugs ranked above placebo for cognition and below placebo for adverse events. We found donepezil 10 mg to rank first in terms of benefit, but third in terms of harms, when considering the network estimates and quality of evidence. Galantamine was ranked second in terms of both benefit and harm. Rivastigmine had the lowest ranking of the cholinesterase inhibitors in both benefit and harm NMA estimates, but this may reflect possibly inadequate doses received by some trial participants and small trial sample sizes., Authors' Conclusions: We found moderate- to high-certainty evidence that donepezil 5 mg, donepezil 10 mg, and galantamine have a slight beneficial effect on cognition in people with VCI, although the size of the change is unlikely to be clinically important. Donepezil 10 mg and galantamine 16 to 24 mg are probably associated with more adverse events than placebo. The evidence for rivastigmine was less certain. The data suggest that donepezil 10 mg has the greatest effect on cognition, but at the cost of adverse effects. The effect is modest, but in the absence of any other treatments, people living with VCI may still wish to consider the use of these agents. Further research into rivastigmine is needed, including the use of transdermal patches., (Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.)
- Published
- 2021
- Full Text
- View/download PDF
26. [Pharmacokinetics/Pharmacodynamic Analysis to Link Pharmacokinetics to Efficacy and Drug Interaction of Alzheimer's Disease Drugs].
- Author
-
Kiriyama A
- Subjects
- Acetylcholine metabolism, Alzheimer Disease metabolism, Animals, Cholinesterase Inhibitors adverse effects, Cilostazol administration & dosage, Cilostazol adverse effects, Donepezil adverse effects, Donepezil blood, Drug Combinations, Drug Interactions, Hippocampus metabolism, Humans, Platelet Aggregation Inhibitors administration & dosage, Platelet Aggregation Inhibitors adverse effects, Rats, Time Factors, Alzheimer Disease drug therapy, Cholinesterase Inhibitors administration & dosage, Cholinesterase Inhibitors pharmacokinetics, Donepezil pharmacokinetics, Donepezil therapeutic use
- Abstract
In recent years, the number of patients with Alzheimer's type dementia continues to increase year by year. As a first-line drug, cholinesterase inhibitor is used. There is a close relationship between the time course of the drug plasma concentration (pharmacokinetics; PK) and the time course of its effects and side effects (pharmacodynamics; PD). However, the relationship between PK and PD is not simply that plasma concentrations are proportional to the effects. The effect is expressed through the characteristics of various pharmacokinetic processes. Therefore, it is important to investigate the transition of effects accompanying its pharmacokinetics. We conducted a fundamental PK/PD analysis using donepezil. Time course of acetylcholine in the hippocampus was investigated with relation to its PK after donepezil administration using rats. The PK and PD characteristics of the drug, including its active metabolite, were investigated. Additionally, Alzheimer's type dementia drugs are often given in combination with antiplatelet drugs such as cilostazol. It is reported that donepezil and cilostazol interact clinically, partly due to inhibition in the efflux transporters in certain tissues. There are various transporters in the body, and interactions through them may cause unexpected changes in the effects. So, it is important to calculate the correlation between the donepezil level in plasma and tissues after their combined administration. From the PK/PD point of view, the results of this study will provide insight into the time course of effects and the characteristics of drug-drug interaction in clinical practice.
- Published
- 2021
- Full Text
- View/download PDF
27. The Association Between Use of Rivastigmine and Pneumonia: Systematic Analysis of FDA Adverse Event Reporting System.
- Author
-
Morris R, Umeukeje G, Bu K, and Cheng F
- Subjects
- Aged, Databases, Factual, Donepezil therapeutic use, Female, Galantamine therapeutic use, Humans, Male, Nootropic Agents therapeutic use, Sex Factors, United States, Adverse Drug Reaction Reporting Systems, Alzheimer Disease complications, Alzheimer Disease drug therapy, Cholinesterase Inhibitors adverse effects, Cholinesterase Inhibitors therapeutic use, Pneumonia chemically induced, Pneumonia epidemiology, Rivastigmine adverse effects, Rivastigmine therapeutic use, United States Food and Drug Administration
- Abstract
Background: Pneumonia is an inflammatory condition induced by infection of the lungs and is frequently a cause of morbidity and mortality among patients with Alzheimer's disease (AD). Some studies have shown an association between acetylcholinesterase inhibitor use and elevated pneumonia risk., Objective: The purpose of this study was to perform a comparative analysis of the number of reported pneumonia cases in individuals prescribed rivastigmine relative to the number of reported cases by patients using other therapeutics including over-the-counter drugs and other AD therapeutics, as reported to the FDA Adverse Event Reporting System (FAERS) database., Methods: A disproportionality analysis was conducted to investigate the association between using rivastigmine and risk of pneumonia. Age, gender, dosage, temporality, and geographic distribution of reported cases were also assessed., Results: Patients prescribed rivastigmine were more likely to report pneumonia as an adverse event than many drugs except galantamine. Males were found to be 46% more likely than females to report pneumonia as an adverse event while likelihood of pneumonia diagnosis increases 3-5-fold in patients older than 65 years of age., Conclusion: The observed elevated frequency of aspiration pneumonia in patients prescribed rivastigmine may be due to an induced cholinergic crisis that is selective for the medulla oblongata, resulting in gastrointestinal distress, impaired swallowing, heightened salivation, and labored breathing. The observed elevated frequency of infectious pneumonia in patients prescribed rivastigmine may also be linked to overstimulation of neurons in the medulla oblongata and downstream suppression of localized inflammatory responses.
- Published
- 2021
- Full Text
- View/download PDF
28. Acute Pancreatitis Caused by Organophosphate Poisoning Complicated by Spontaneous Rupture of Acute Necrotic Collection: A Case Report.
- Author
-
Qu C, Wei M, Zhang H, Zhang J, Ke L, and Li W
- Subjects
- Female, Humans, Middle Aged, Organophosphate Poisoning diagnosis, Organophosphate Poisoning therapy, Pancreatitis, Acute Necrotizing diagnosis, Pancreatitis, Acute Necrotizing therapy, Peritonitis etiology, Rupture, Spontaneous, Shock, Septic etiology, Suicide, Attempted, Treatment Outcome, Cholinesterase Inhibitors adverse effects, Dichlorvos adverse effects, Organophosphate Poisoning complications, Pancreatitis, Acute Necrotizing chemically induced
- Published
- 2021
- Full Text
- View/download PDF
29. Bradycardia Due to Donepezil in Adults: Systematic Analysis of FDA Adverse Event Reporting System.
- Author
-
Morris R, Luboff H, Jose RP, Eckhoff K, Bu K, Pham M, Rohlsen-Neal D, and Cheng F
- Subjects
- Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Alzheimer Disease drug therapy, Bradycardia chemically induced, Cholinesterase Inhibitors adverse effects, Donepezil adverse effects, Nootropic Agents adverse effects
- Abstract
Background: Bradycardia is a physiological condition characterized by a decrease in heart rate and is a side effect of many drug classes. Bradycardia has been reported as an adverse event for patients receiving donepezil for Alzheimer's disease (AD) treatment., Objective: The purpose of the paper is to systematically investigate the association between the occurrence of bradycardia in adults and the usage of donepezil using clinical data derived from the FDA Adverse Event Reporting System (FAERS) database., Methods: The risk of bradycardia in patients who only took donepezil was compared with those of patients who only took over-the-counter medications, multiple arrhythmia drugs, or other medications for AD treatment. In addition, this study sought to determine if this heightened bradycardia risk was influenced by sex, age, and dosage., Results: The results indicated that there was a significant greater likelihood of reporting bradycardia in patients administered donepezil than most of the drugs investigated. There was no significant association between age or the dosage of donepezil and the likelihood of reporting bradycardia. However, males were found to be more likely than females to report bradycardia as an adverse event. Tumor necrosis factor inhibition and the stimulation of endothelial nitric oxide synthase were proposed to be the primary mechanism of actions which confer elevated bradycardia risk when using donepezil., Conclusion: These findings identified strong association between the usage of donepezil and bradycardia in adults as well as provided insight into the underlying molecular mechanisms that induce bradycardia by donepezil.
- Published
- 2021
- Full Text
- View/download PDF
30. Gestational exposures to organophosphorus insecticides: From acute poisoning to developmental neurotoxicity.
- Author
-
Todd SW, Lumsden EW, Aracava Y, Mamczarz J, Albuquerque EX, and Pereira EFR
- Subjects
- Animals, Female, Humans, Neurodevelopmental Disorders diagnosis, Neurotoxicity Syndromes diagnosis, Neurotoxicity Syndromes etiology, Pregnancy, Prenatal Exposure Delayed Effects diagnosis, Cholinesterase Inhibitors adverse effects, Insecticides adverse effects, Neurodevelopmental Disorders chemically induced, Organophosphorus Compounds adverse effects, Prenatal Exposure Delayed Effects chemically induced
- Abstract
For over three-quarters of a century, organophosphorus (OP) insecticides have been ubiquitously used in agricultural, residential, and commercial settings and in public health programs to mitigate insect-borne diseases. Their broad-spectrum insecticidal effectiveness is accounted for by the irreversible inhibition of acetylcholinesterase (AChE), the enzyme that catalyzes acetylcholine (ACh) hydrolysis, in the nervous system of insects. However, because AChE is evolutionarily conserved, OP insecticides are also toxic to mammals, including humans, and acute OP intoxication remains a major public health concern in countries where OP insecticide usage is poorly regulated. Environmental exposures to OP levels that are generally too low to cause marked inhibition of AChE and to trigger acute signs of intoxication, on the other hand, represent an insidious public health issue worldwide. Gestational exposures to OP insecticides are particularly concerning because of the exquisite sensitivity of the developing brain to these insecticides. The present article overviews and discusses: (i) the health effects and therapeutic management of acute OP poisoning during pregnancy, (ii) epidemiological studies examining associations between environmental OP exposures during gestation and health outcomes of offspring, (iii) preclinical evidence that OP insecticides are developmental neurotoxicants, and (iv) potential mechanisms underlying the developmental neurotoxicity of OP insecticides. Understanding how gestational exposures to different levels of OP insecticides affect pregnancy and childhood development is critical to guiding implementation of preventive measures and direct research aimed at identifying effective therapeutic interventions that can limit the negative impact of these exposures on public health., (Copyright © 2020 Elsevier Ltd. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
31. Design, synthesis and evaluation of quinolinone derivatives containing dithiocarbamate moiety as multifunctional AChE inhibitors for the treatment of Alzheimer's disease.
- Author
-
Fu J, Bao F, Gu M, Liu J, Zhang Z, Ding J, Xie SS, and Ding J
- Subjects
- Animals, Blood-Brain Barrier metabolism, Cholinesterase Inhibitors administration & dosage, Cholinesterase Inhibitors adverse effects, Drug Design, Female, Humans, Male, Mice, Molecular Docking Simulation, Protein Binding, Quinolones administration & dosage, Quinolones adverse effects, Acetylcholinesterase metabolism, Alzheimer Disease drug therapy, Cholinesterase Inhibitors chemistry, Quinolones chemistry, Thiocarbamates chemistry
- Abstract
A series of novel quinolinone derivatives bearing dithiocarbamate moiety were designed and synthesised as multifunctional AChE inhibitors for the treatment of AD. Most of these compounds exhibited strong and clearly selective inhibition to ee AChE. Among them, compound 4c was identified as the most potent inhibitor to both ee AChE and h AChE (IC
50 = 0.22 μM for eeAChE; IC50 = 0.16 μM for h AChE), and it was also the best inhibitor to AChE-induced Aβ aggregation (29.02% at 100 μM) and an efficient inhibitor to self-induced Aβ aggregation (30.67% at 25 μM). Kinetic and molecular modelling studies indicated that compound 4c was a mixed-type inhibitor, which could interact simultaneously with the catalytic anionic site (CAS) and the peripheral anionic site (PAS) of AChE. In addition, 4c had good ability to cross the BBB, showed no toxicity on SH-SY5Y neuroblastoma cells and was well tolerated in mice at doses up to 2500 mg/kg (po).- Published
- 2020
- Full Text
- View/download PDF
32. Re-pigmentation of hair after prolonged cholinesterase inhibitor therapy in a Chinese population.
- Author
-
Chan LKM, Braidy N, Ng W, Xu YH, Chen J, McDonald R, and Chan DKY
- Subjects
- Aged, Alzheimer Disease drug therapy, Asian People, Female, Humans, Male, Cholinesterase Inhibitors adverse effects, Hair Color drug effects
- Abstract
Eighty consecutive Chinese patients diagnosed with Alzheimer disease were assessed for darkening of grey hair. Of the 62 eligible patients (mean age = 79.3 ± 7.9 years; male: female = 1:1.48), 24/62 (38.7%, 95%CI: 26.6 - 51.9) reported hair darkening after prolonged usage of cholinesterase inhibitor for at least 6 months. Of the 24 patients with hair darkening, 17 (70.9%) experienced hair darkening in the occipital region, 3 (12.5%) in the parietal region, 2 (8.3%) patients in the frontal region and 2 (8.3%) patients experienced hair darkening in multiple regions. Analysis of melanin concentration showed no significant difference between darkened hair of patients after prolonged drug use and the dark hair of controls (P = 0.381)., (© 2020 The Australasian College of Dermatologists.)
- Published
- 2020
- Full Text
- View/download PDF
33. Exposure to cholinesterase inhibiting insecticides and blood glucose level in a population of Ugandan smallholder farmers.
- Author
-
Hansen MRH, Jørs E, Sandbæk A, Sekabojja D, Ssempebwa JC, Mubeezi R, Staudacher P, Fuhrimann S, Burdorf A, Bibby BM, and Schlünssen V
- Subjects
- Adult, Cholinesterase Inhibitors therapeutic use, Female, Humans, Insecticides therapeutic use, Male, Middle Aged, Occupational Exposure adverse effects, Occupational Exposure statistics & numerical data, Surveys and Questionnaires, Uganda, Blood Glucose analysis, Cholinesterase Inhibitors adverse effects, Farmers statistics & numerical data, Insecticides adverse effects
- Abstract
Objectives: The risk of diabetes mellitus may be elevated among persons exposed to some pesticides, including cholinesterase-inhibiting insecticides (organophosphates and carbamates). The objective of this study was to investigate how acetylcholinesterase activity was associated with mean blood glucose levels among smallholder farmers in Uganda., Methods: We conducted a short-term follow-up study among 364 smallholder farmers in Uganda. Participants were examined three times from September 2018 to February 2019. At each visit, we measured glycosylated haemoglobin A (HbA
1c ) as a measure of long-term average blood glucose levels. Exposure to organophosphate and carbamate insecticides was quantified using erythrocyte acetylcholinesterase normalised by haemoglobin (AChE/Hb). For a subgroup of participants, fasting plasma glucose (FPG) was also available. We analysed HbA1c and FPG versus AChE/Hb in linear mixed and fixed effect models adjusting for age, sex, physical activity level, and consumption of fruits and vegetables, alcohol and tobacco., Results: Contrary to our hypothesis, our mixed effect models showed significant correlation between low AChE/Hb and low HbA1c . Adjusted mean HbA1c was 0.74 (95% CI 0.17 to 1.31) mmol/mol lower for subjects with AChE/Hb=24.3 U/g (35th percentile) compared with subjects with AChE/Hb=25.8 U/g (50th percentile). Similar results were demonstrated for FPG. Fixed effect models showed less clear correlations for between-phase changes in AChE/Hb and HbA1c ., Conclusions: Our results do not clearly support a causal link between exposure to cholinesterase-inhibiting insecticides and elevated blood glucose levels (expressed as HbA1c and FPG), but results should be interpreted with caution due to the risk of reverse causality., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)- Published
- 2020
- Full Text
- View/download PDF
34. Postoperative Administration of the Acetylcholinesterase Inhibitor, Donepezil, Interferes with Bone Healing and Implant Osseointegration in a Rat Model.
- Author
-
Al-Hamed FS, Maria OM, Phan J, Al Subaie A, Gao Q, Mansour A, Abu Nada L, Boukhatem I, Elkashty OA, Tran SD, Lordkipanidzé M, Badran Z, and Tamimi F
- Subjects
- Animals, Bone Substitutes chemistry, Bone-Implant Interface diagnostic imaging, Female, Rats, Rats, Sprague-Dawley, Tibia diagnostic imaging, Tibia drug effects, Tibia injuries, Tibial Fractures diagnostic imaging, Titanium chemistry, X-Ray Microtomography, Bone-Implant Interface pathology, Cholinesterase Inhibitors adverse effects, Donepezil adverse effects, Osseointegration drug effects, Tibial Fractures pathology, Wound Healing drug effects
- Abstract
Donepezil is an acetylcholinesterase inhibitor commonly used to treat mild to moderate Alzheimer's disease. Its use has been associated with increased bone mass in humans and animals. However, the effect of postoperative administration of donepezil on bone healing remains unknown. Therefore, this study aimed to assess the impact of postoperative injection of donepezil on bone healing, titanium-implant osseointegration, and soft tissue healing. Twenty-two Sprague-Dawley rats were randomly assigned to receive a daily dose of either donepezil (0.6 mg/kg) or saline as a control. In each rat, a uni-cortical defect was created in the right tibia metaphysis and a custom-made titanium implant was placed in the left tibiae. After two weeks, rats were euthanized, and their bones were analysed by Micro-CT and histology. The healing of bone defect and implant osseointegration in the rats treated with donepezil were significantly reduced compared to the saline-treated rats. Histomorphometric analysis showed lower immune cell infiltration in bone defects treated with donepezil compared to the saline-treated defects. On the other hand, the healing time of soft tissue wounds was significantly shorter in donepezil-treated rats compared to the controls. In conclusion, short-term administration of donepezil hinders bone healing whereas enhancing soft tissue healing.
- Published
- 2020
- Full Text
- View/download PDF
35. Merged Tacrine-Based, Multitarget-Directed Acetylcholinesterase Inhibitors 2015-Present: Synthesis and Biological Activity.
- Author
-
Eckroat TJ, Manross DL, and Cowan SC
- Subjects
- Acetylcholinesterase chemistry, Acetylcholinesterase metabolism, Animals, Cholinesterase Inhibitors adverse effects, Cholinesterase Inhibitors pharmacology, Drug Discovery, Humans, Liver drug effects, Neuroprotective Agents adverse effects, Neuroprotective Agents pharmacology, Cholinesterase Inhibitors chemical synthesis, Neuroprotective Agents chemical synthesis, Tacrine analogs & derivatives
- Abstract
Acetylcholinesterase is an important biochemical enzyme in that it controls acetylcholine-mediated neuronal transmission in the central nervous system, contains a unique structure with two binding sites connected by a gorge region, and it has historically been the main pharmacological target for treatment of Alzheimer's disease. Given the large projected increase in Alzheimer's disease cases in the coming decades and its complex, multifactorial nature, new drugs that target multiple aspects of the disease at once are needed. Tacrine, the first acetylcholinesterase inhibitor used clinically but withdrawn due to hepatotoxicity concerns, remains an important starting point in research for the development of multitarget-directed acetylcholinesterase inhibitors. This review highlights tacrine-based, multitarget-directed acetylcholinesterase inhibitors published in the literature since 2015 with a specific focus on merged compounds (i.e., compounds where tacrine and a second pharmacophore show significant overlap in structure). The synthesis of these compounds from readily available starting materials is discussed, along with acetylcholinesterase inhibition data, relative to tacrine, and structure activity relationships. Where applicable, molecular modeling, to elucidate key enzyme-inhibitor interactions, and secondary biological activity is highlighted. Of the numerous compounds identified, there is a subset with promising preliminary screening results, which should inspire further development and future research in this field.
- Published
- 2020
- Full Text
- View/download PDF
36. The effects of acetylcholinesterase inhibitors on morbidity after general anesthesia and surgery.
- Author
-
Shay D, Wongtangman K, Eikermann M, and Schaefer MS
- Subjects
- Cardiovascular System drug effects, Humans, Morbidity, Neostigmine adverse effects, Neostigmine pharmacology, Neostigmine therapeutic use, Neuromuscular Blockade adverse effects, Perioperative Care methods, Postoperative Complications prevention & control, Respiratory System drug effects, Anesthesia, General methods, Cholinesterase Inhibitors adverse effects, Cholinesterase Inhibitors pharmacology, General Surgery methods
- Abstract
Non-depolarizing neuromuscular blocking agents are used during general anesthesia to facilitate intubation and optimize surgical conditions. When patients leave the operating room after surgery, postoperative residual neuromuscular block occurs frequently, increasing vulnerability to respiratory complications such as hypoxemia and unplanned postoperative mechanical ventilation. To restore neuromuscular transmission and skeletal muscle strength, anesthesiologists typically administer peripherally acting acetylcholinesterase inhibitors such as neostigmine. However, neostigmine's desirable effects have a narrow therapeutic range. Even at recommended dose (15-50 μg/kg), neostigmine induces nicotinic (upper airway muscle weakness leading to dysphagia and upper airway obstruction, and decreased maximum inspiratory airflow) and muscarinic (blurred vision, bronchial constriction, abdominal cramping and nausea) side effects. Recent data have questioned as to whether neostigmine reversal of neuromuscular blockade improves relevant patient outcomes such as postoperative respiratory and perioperative cardiovascular complications. A central strategy to avoid side effects of neuromuscular blocking agents is their judicious use based on quantitative monitoring of neuromuscular transmission using repetitive peripheral nerve stimulation (train-of-four ratio). Peripherally acting acetylcholinesterase inhibitors such as neostigmine should then only be administered when indicated and dosed based on results of the train-of-four ratio., Competing Interests: Declaration of competing interest All other authors declare no conflict of interest., (Copyright © 2020 Elsevier Ltd. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
37. Comparative risk of cardiac arrhythmias associated with acetylcholinesterase inhibitors used in treatment of dementias - A narrative review.
- Author
-
Huang Y and Alsabbagh MW
- Subjects
- Alzheimer Disease drug therapy, Animals, Arrhythmias, Cardiac physiopathology, Cholinesterase Inhibitors administration & dosage, Dementia drug therapy, Donepezil administration & dosage, Donepezil adverse effects, Galantamine administration & dosage, Galantamine adverse effects, Humans, Rivastigmine administration & dosage, Rivastigmine adverse effects, Arrhythmias, Cardiac chemically induced, Cholinesterase Inhibitors adverse effects
- Abstract
Donepezil, galantamine, and rivastigmine are the three acetylcholinesterase inhibitors (AChEIs), out of a total of only four medications prescribed in the treatment of Alzheimer's Disease (AD) and related dementias. These medications are known to be associated with bradycardia given their mechanism of action of increasing acetylcholine (ACh). However, in March 2015, donepezil was added to the CredibleMeds "known-risk" category, a list where medications have a documented risk for acquired long-QT syndrome (ALQTS) and torsades de pointes (TdP) - a malignant ventricular arrhythmia that is a different adverse event than bradycardia (and is not necessarily associated with ACh action). The purpose of this article is to review the three AChEIs, especially with regards to mechanistic differences that may explain why only donepezil poses this risk; several pharmacological mechanisms may explain why. However, from an empirical point-of-view, aside from some case-reports, only a limited number of studies have generated relevant information regarding AChEIs' and electrocardiogram findings; none have specifically compared donepezil against galantamine or rivastigmine for malignant arrhythmias such as TdP. Currently, the choice of one of the three AChEIs for treatment of AD symptoms is primarily dependent upon clinician and patient preference. However, clinicians should be aware of the potential increased risk associated with donepezil. There is a need to examine the comparative risk of malignant arrhythmias among AChEIs users in real-world practice; this may have important implications with regards to changes in AChEI prescribing patterns., (© 2020 The Authors. Pharmacology Research & Perspectives published by John Wiley & Sons Ltd, British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics.)
- Published
- 2020
- Full Text
- View/download PDF
38. TV 3326 for Alzheimer's dementia: a novel multimodal ChE and MAO inhibitors to mitigate Alzheimer's-like neuropathology.
- Author
-
Uddin MS, Kabir MT, Rahman MM, Mathew B, Shah MA, and Ashraf GM
- Subjects
- Acetylcholinesterase metabolism, Alzheimer Disease enzymology, Alzheimer Disease pathology, Alzheimer Disease physiopathology, Animals, Brain enzymology, Brain pathology, Cholinesterase Inhibitors adverse effects, GPI-Linked Proteins antagonists & inhibitors, GPI-Linked Proteins metabolism, Humans, Indans adverse effects, Monoamine Oxidase Inhibitors adverse effects, Nootropic Agents adverse effects, Alzheimer Disease drug therapy, Brain drug effects, Butyrylcholinesterase metabolism, Cholinesterase Inhibitors therapeutic use, Indans therapeutic use, Memory drug effects, Monoamine Oxidase Inhibitors therapeutic use, Nootropic Agents therapeutic use
- Abstract
Objectives: Alzheimer's disease (AD) is one of the most prevalent neurodegenerative disorders and a well-recognized cause of dementia with ageing. In this review, we have represented the ChE and MAO inhibitory potential of TV 3326 against AD based on current scientific evidence., Key Findings: The aetiology of AD is quite complex and not completely understood. However, it has been observed that AD involves the deposition of abnormal amyloid beta (Aβ), along with hyperphosphorylation of tau, oxidative stress, low acetylcholine (ACh) level and biometal dyshomeostasis. Due to the complex nature of AD aetiology, active research is required in the areas of development of multitarget drugs with 2 or more complementary biological functions, as they might represent significant progress in the AD treatment. Interestingly, it has been found that TV 3326 (i.e. ladostigil) is regarded as a novel therapeutic agent since it has the potential to cause inhibition of monoamine oxidase (MAO) A and B, and acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) in the brain. Furthermore, it has the capacity to reverse memory impairments, which further suggests the ability of this drug to elevate cholinergic activity in the brain., Summary: TV 3326 can avert oxidative-nitrative stress and gliosis. It has also been confirmed that TV 3326 contains neuroprotective and anti-apoptotic properties. Therefore, this distinctive combined inhibition of ChE and MAO along with its neuroprotective property makes TV 3326 a useful drug in the treatment of AD., (© 2020 Royal Pharmaceutical Society.)
- Published
- 2020
- Full Text
- View/download PDF
39. New Tetrahydroacridine Hybrids with Dichlorobenzoic Acid Moiety Demonstrating Multifunctional Potential for the Treatment of Alzheimer's Disease.
- Author
-
Czarnecka K, Girek M, Wójtowicz P, Kręcisz P, Skibiński R, Jończyk J, Łątka K, Bajda M, Walczak A, Galita G, Kabziński J, Majsterek I, Szymczyk P, and Szymański P
- Subjects
- Amyloid beta-Protein Precursor metabolism, Animals, Catalytic Domain, Cell Line, Tumor, Cells, Cultured, Cholinesterase Inhibitors adverse effects, Cholinesterase Inhibitors pharmacology, Cholinesterase Inhibitors therapeutic use, Cholinesterases chemistry, Cholinesterases metabolism, Free Radical Scavengers adverse effects, Free Radical Scavengers chemical synthesis, Free Radical Scavengers pharmacology, Free Radical Scavengers therapeutic use, Humans, Hyaluronoglucosaminidase antagonists & inhibitors, Mice, Molecular Docking Simulation, Neuroprotective Agents adverse effects, Neuroprotective Agents pharmacology, Neuroprotective Agents therapeutic use, Protein Binding, Protein Multimerization drug effects, Alzheimer Disease drug therapy, Chlorobenzoates chemistry, Cholinesterase Inhibitors chemical synthesis, Neuroprotective Agents chemical synthesis, Tacrine analogs & derivatives
- Abstract
A series of new tetrahydroacridine and 3,5-dichlorobenzoic acid hybrids with different spacers were designed, synthesized, and evaluated for their ability to inhibit both cholinesterase enzymes. Compounds 3a , 3b , 3f , and 3g exhibited selective butyrylcholinesterase ( Eq BuChE) inhibition with IC
50 values ranging from 24 to 607 nM. Among them, compound 3b was the most active (IC50 = 24 nM). Additionally, 3c (IC50 for Ee AChE = 25 nM and IC50 for Eq BuChE = 123 nM) displayed dual cholinesterase inhibitory activity and was the most active compound against acetylcholinesterase (AChE). Active compound 3c was also tested for the ability to inhibit Aβ aggregation. Theoretical physicochemical properties of the compounds were calculated using ACD Labs Percepta and Chemaxon. A Lineweaver-Burk plot and docking study showed that 3c targeted both the catalytic active site (CAS) and the peripheral anionic site (PAS) of AChE. Moreover, 3c appears to possess neuroprotective activity and could be considered a free-radical scavenger. In addition, 3c did not cause DNA damage and was found to be less toxic than tacrine after oral administration; it also demonstrated little inhibitory activity towards hyaluronidase (HYAL), which may indicate that it possesses anti-inflammatory properties. The screening for new in vivo interactions between 3c and known receptors was realized by yeast three-hybrid technology (Y3H).- Published
- 2020
- Full Text
- View/download PDF
40. Pisa syndrome induced by switching of a choline-esterase inhibitor treatment from donepezil to galantamine: a case report.
- Author
-
Mimura Y, Kurose S, Takata T, Tabuchi H, Mimura M, and Funayama M
- Subjects
- Donepezil therapeutic use, Female, Humans, Middle Aged, Alzheimer Disease drug therapy, Cholinesterase Inhibitors adverse effects, Galantamine adverse effects, Tardive Dyskinesia chemically induced
- Abstract
Background: Pisa syndrome (PS) is characterized by an abnormally sustained posture, with flexion of the body and head to one side and slight rotation of the trunk. Although PS most commonly arises as an adverse effect of antipsychotic drugs, choline-esterase inhibitors (ChEIs) are also sometimes known to induce PS. Despite the fact that the precise mechanism remains unclear, cholinergic-dopaminergic imbalance has been considered as a possible pathophysiologic mechanism underlying the genesis of PS., Case Presentation: We hereby report the case of a 60-year-old woman with Alzheimer's disease who presented with the signs of PS after her treatment was switched to galantamine, a type of ChEI, even though she had received donepezil, another type of ChEI, for 5 years without any complications. To the best of our knowledge, this is the first report of PS associated with treatment switch from one to another type of ChEI. Galantamine, but not other ChEIs, can enhance striatal dopamine release through allosteric modulation of the nicotinic acetylcholine receptor, and has weaker muscarinic effects than donepezil. Therefore, we propose two novel hypotheses to explain the development of PS, as follows; galantamine, which enhances dopamine release, can induce imbalance of dopamine levels in the striatum of patients with dementia, resulting in PS, and the weaker muscarinic effects of the drug could be one of the factors predisposing to the development of PS., Conclusion: The present case suggests that treatment with galantamine is associated with a higher risk of development of PS than that with other ChEIs, such as donepezil, despite the pharmacological profile of galantamine as a dopamine modulator. Also, this report provides novel insight into another plausible mechanism underlying the development of PS, besides cholinergic-dopaminergic imbalance, namely, dopamine imbalance in the striatum with muscarinic-nicotinic imbalance.
- Published
- 2020
- Full Text
- View/download PDF
41. Efficacy and safety of MAO-B inhibitor versus donepezil in Chinese elderly stroke patients with Alzheimer disease: A potential therapeutic option.
- Author
-
Yang H, Han W, and Li H
- Subjects
- Age Factors, Aged, Alzheimer Disease complications, Alzheimer Disease diagnosis, Alzheimer Disease psychology, China, Cholinesterase Inhibitors adverse effects, Donepezil adverse effects, Female, Humans, Male, Monoamine Oxidase Inhibitors adverse effects, Nootropic Agents adverse effects, Pilot Projects, Random Allocation, Selegiline adverse effects, Stroke diagnosis, Stroke psychology, Time Factors, Treatment Outcome, Alzheimer Disease drug therapy, Cholinesterase Inhibitors therapeutic use, Cognition drug effects, Donepezil therapeutic use, Monoamine Oxidase Inhibitors therapeutic use, Nootropic Agents therapeutic use, Selegiline therapeutic use, Stroke complications
- Abstract
This pilot study designed to evaluate the efficacy and safety of MAO-B inhibitor in comparison with Donepezil (DNP) in elderly Chinese patients with Alzheimer disease (AD). In the present clinical trial, Chinese elderly patients aged ≥65 years with a confirmed diagnosis of AD were enrolled. The patients received MAO-B inhibitor (Selegiline 5 mg) or DNP 10 mg daily (reference) for 6 months. The efficacy and safety data were collected from 120 patients (60 patients in each group) every 3 weeks until 6 months. The primary endpoints were to assess the change in cognitive score from baseline in both the treatment group. The result of the present study showed that the patients treated with MAO-B inhibitor and DNP have similar efficacy and safety profile Considering the clinical benefit, mean (SD) improvement in sign and symptoms was numerically greater in DNP-treated patients as compared to MAO-B inhibitor at endpoint visit (SIB: 12.3 (3.7) vs 11.3 (4.2); AD severity: 14.2 (3.5); CIBIS+/CIBIC: 10.2 (2.7) vs 9.4 (3.2); ADCS-ADL: 14.3 (4.2) vs 13.2 (3.4); MMSE: 14.3 (3.7) vs 12.2 (3.2), P>0.05 respectively for each comparison). However, a statistical difference in terms of clinical benefit was similar between both the treatment groups (p>0.05). Overall, both the study drugs were found comparable in relieving the symptoms of AD (severity score after end of treatment: 14.2 vs 13.4 respectively; p >0.05). This indicates that MAO-B inhibitor is a potential target for the treatment of AD in China. The results of the present study may help to design a large clinical trial to evaluate the efficacy and safety of MAO-B inhibitor in comparison with DNP in AD patients.
- Published
- 2020
42. Impact of deprescribing AChEIs on aggressive behaviors and antipsychotic prescribing.
- Author
-
Niznik JD, Zhao X, He M, Aspinall SL, Hanlon JT, Nace D, Thorpe JM, and Thorpe CT
- Subjects
- Aged, Dementia complications, Dementia drug therapy, Female, Humans, Insurance Claim Review statistics & numerical data, Male, Medicare, Nursing Homes, Retrospective Studies, United States, Aggression drug effects, Antipsychotic Agents adverse effects, Cholinesterase Inhibitors adverse effects, Deprescriptions
- Abstract
Introduction: We evaluated the impact of deprescribing acetylcholinesterase inhibitors (AChEIs) on aggressive behaviors and incident antipsychotic use in nursing home (NH) residents with severe dementia., Methods: We conducted a retrospective study of Medicare claims, Part D, Minimum Data Set for NH residents aged 65+ with severe dementia receiving AChEIs in 2016. Aggressive behaviors were measured using the aggressive behavior scale (ABS; n = 30,788). Incident antipsychotic prescriptions were evaluated among antipsychotic non-users (n = 25,188). Marginal structural models and inverse probability of treatment weights were used to evaluate associations of AChEI deprescribing and outcomes., Results: The severity of aggressive behaviors was low at baseline (mean ABS = 0.5) and was not associated with deprescribing AChEIs (0.002 increase in ABS, P = .90). Incident antipsychotic prescribing occurred in 5.1% of residents and was less likely with AChEI deprescribing (adjusted odds ratio = 0.52 [0.40-0.68], P <.001])., Discussion: Deprescribing AChEIs was not associated with a worsening of aggressive behaviors or incident antipsychotic prescriptions., (© 2020 the Alzheimer's Association.)
- Published
- 2020
- Full Text
- View/download PDF
43. Risk for Health Events After Deprescribing Acetylcholinesterase Inhibitors in Nursing Home Residents With Severe Dementia.
- Author
-
Niznik JD, Zhao X, He M, Aspinall SL, Hanlon JT, Hanson LC, Nace D, Thorpe JM, and Thorpe CT
- Subjects
- Accidental Falls prevention & control, Aged, Aged, 80 and over, Cholinesterase Inhibitors administration & dosage, Dementia epidemiology, Female, Humans, Longitudinal Studies, Male, Medicare statistics & numerical data, Retrospective Studies, Risk Assessment, United States epidemiology, Cholinesterase Inhibitors adverse effects, Dementia drug therapy, Deprescriptions, Homes for the Aged statistics & numerical data, Nursing Homes statistics & numerical data
- Abstract
Background/objective: Reevaluation of the appropriateness of acetylcholinesterase inhibitors (AChEIs) is recommended in older adults with severe dementia, given the lack of strong evidence to support their continued effectiveness and risk for medication-induced adverse events. We sought to evaluate the impact of deprescribing AChEIs on risk of all-cause events (hospitalizations, emergency department visits, and mortality) and serious falls or fractures in older nursing home (NH) residents with severe dementia., Design: Analysis of 2015 to 2016 data from Medicare claims, Part D prescriptions, Minimum Data Set (MDS) version 3.0, Area Health Resource File, and Nursing Home Compare. Marginal structural models with inverse probability of treatment weights were used to evaluate the association of deprescribing AChEIs and all-cause negative events as well as serious falls or fractures., Setting: US Medicare-certified NHs., Participants: Nonskilled NH residents, aged 65 years and older, with severe dementia receiving AChEIs within the first 14 days of an MDS assessment in 2016 (n = 37 106)., Results: The sample was primarily white (78.7%), female (75.5%), and aged 80 years or older (77.4%). Deprescribing AChEIs was associated with an increased likelihood of all-cause negative events in unadjusted models (odds ratio [OR] = 1.17; 95% confidence interval [CI] = 1.11-1.23; P < .01), but not in fully adjusted models (adjusted OR [aOR] = 1.00; 95% CI = 0.94-1.06; P = .94). By contrast, deprescribing was associated with a reduced likelihood of serious falls or fractures in unadjusted models (OR = 0.59; 95% CI = 0.52-0.66; P < .001) and remained significant in adjusted models (aOR = 0.64; 95% CI = 0.56-0.73; P < .001)., Conclusion: Deprescribing AChEIs was not associated with a significant increase in the likelihood for all-cause negative events and was associated with a reduced likelihood of falls and fractures in older NH residents with dementia. Our findings suggest that deprescribing AChEIs is a reasonable approach to reduce the risk of serious falls or fractures without increasing the risk for all-cause events. J Am Geriatr Soc 68:699-707, 2020., (© 2019 The American Geriatrics Society.)
- Published
- 2020
- Full Text
- View/download PDF
44. Determinants of antidementia drug prescription in patients older than 65: A latent class analysis.
- Author
-
François M, Sicsic J, and Pelletier-Fleury N
- Subjects
- Aged, Aged, 80 and over, Cholinesterase Inhibitors adverse effects, Cross-Sectional Studies, Drug Prescriptions statistics & numerical data, Female, France epidemiology, Humans, Male, Memantine adverse effects, Cholinesterase Inhibitors administration & dosage, Databases, Factual statistics & numerical data, Dementia drug therapy, Dementia epidemiology, Latent Class Analysis, Memantine administration & dosage
- Abstract
Background: Antidementia drugs (cholinesterase inhibitors and memantine) are still widely prescribed despite their controversial effects and 2011 guidelines that no longer encourage their prescription. The objective was to assess which factors remained determinants of antidementia drug prescriptions., Methods: A cross-sectional study was performed in 2013. Patients suffering from dementia, aged 65 and over, identified in the French national health insurance database were included. Because we anticipated a high correlation between age, comorbidities, and health care use, we first identified the patients' health status by a latent class analysis. Second, we performed adjusted logistic regression models. The explanatory variables were patients' health status, gender, prescription of nonpharmacological treatments (physical and speech therapies), prescription of psychotropic drugs, and access to health care., Results: Among the 3873 patients included, 38% received antidementia drugs. Three latent classes of patients with different health status were identified. Patients with poor health status received significantly fewer antidementia drugs (P < .001). Patients with speech therapy or antidepressant drugs received significantly more antidementia drugs (P < .001), whereas patients with physical therapy received significantly fewer antidementia drugs (P = .006)., Conclusion: Antidementia drugs were less likely to be prescribed for patients with poor health status. This result is encouraging for these frail patients who are more vulnerable to the adverse effects of treatments. At the same time, this result encourage targeting specifically patients in good health status for the use of a decision aid, in an attempt to limit prescriptions by involving patients and families., (© 2020 John Wiley & Sons Ltd.)
- Published
- 2020
- Full Text
- View/download PDF
45. Extrapyramidal side effect of donepezil hydrochloride in an elderly patient: A case report.
- Author
-
Li HC, Luo KX, Wang JS, and Wang QX
- Subjects
- Aged, 80 and over, Female, Humans, Alzheimer Disease drug therapy, Cholinesterase Inhibitors adverse effects, Donepezil adverse effects, Drug-Related Side Effects and Adverse Reactions
- Abstract
Introduction: Alzheimer disease (AD) is a neurodegenerative disease characterized by progressive cognitive dysfunction, which is mainly manifested as memory impairment and a reduced ability to self-care, often accompanied by neuropsychiatric and behavioral disorders. Donepezil is the second drug to be approved by the US FDA for the treatment of AD. Of the five FDA-approved drugs for AD treatment, donepezil is currently the most widely used. Here, we report an extrapyramidal adverse reaction to donepezil in an elderly patient with AD., Patient Concerns: An 87-year-old woman presented with a 1-year history of forgetfulness that was aggravated since the past 2 months. She had a long-term history of multiple major conditions, including hypertension, diabetes, osteoporosis, and arterial plaques. Brain imaging showed age-related changes, and her Mini Mental State Examination score was 20. Other tests revealed no abnormalities apart from multiple thyroid nodules on ultrasonography., Diagnosis: She was diagnosed with AD, hypertension, type 2 diabetes mellitus, diabetic neuropathy, osteoporosis, carotid and lower-extremity arterial plaques, thyroid nodules., Interventions: She was treated with donepezil (5 mg/day), amlodipine besylate (5 mg/day), glimepiride (4 mg/day), methylcobalamin (1.5 mg/day), calcium carbonate D3 (600 mg/day), simvastatin (20 mg/day) and enteric-coated aspirin (100 mg/day)., Outcomes: Four days later, she experienced fatigue, panic, sweating, and one episode of vomiting. On the 5th day, she developed increased muscle tension, speech difficulty, and involuntary tremors. Imaging and blood tests revealed no obvious abnormality, and the patient was not receiving psychotropic drugs. An extrapyramidal adverse reaction to donepezil was considered, and the drug was discontinued, after which the symptoms gradually disappeared., Conclusion: Serious adverse reactions to donepezil can occur in elderly patients, who typically require multiple medications for a variety of comorbidities. In particular, extrapyramidal reactions have occurred when donepezil is administered in combination with psychotropic drugs. However, in our patient, an extrapyramidal adverse reaction occurred in the absence of psychotropic drugs. Thus, clinicians must be aware of inter-individual differences in drug actions and possible serious adverse reactions, and carefully monitor these patients to ensure the timely detection of adverse events and their safe treatment.
- Published
- 2020
- Full Text
- View/download PDF
46. Effects of Anticholinesterase Reversal Under General Anesthesia on Postoperative Cardiovascular Complications: A Retrospective Cohort Study.
- Author
-
Shay D, Scheffenbichler FT, Kelly BJ, Lihn AL, Deng H, Nourmahnad A, Xu X, Houle TT, Eikermann M, and Forman SA
- Subjects
- Adult, Aged, Boston epidemiology, Bradycardia diagnosis, Bradycardia epidemiology, Bradycardia physiopathology, Female, Humans, Male, Middle Aged, Registries, Retrospective Studies, Risk Assessment, Risk Factors, Tachycardia diagnosis, Tachycardia epidemiology, Tachycardia physiopathology, Time Factors, Treatment Outcome, Anesthesia, General adverse effects, Bradycardia chemically induced, Cholinesterase Inhibitors adverse effects, Glycopyrrolate adverse effects, Heart Rate drug effects, Muscarinic Antagonists adverse effects, Neostigmine adverse effects, Surgical Procedures, Operative adverse effects, Tachycardia chemically induced
- Abstract
Background: The anticholinesterase neostigmine and the muscarinic inhibitor glycopyrrolate are frequently coadministered for the reversal of neuromuscular blockade. This practice can precipitate severe bradycardia or tachycardia, but whether it affects the incidence of cardiovascular complications remains unclear. We hypothesized that anticholinesterase reversal with neostigmine and glycopyrrolate versus no anticholinesterase reversal increases the risk of postoperative cardiovascular complications among adult patients undergoing noncardiac surgery with general anesthesia., Methods: We conducted a prespecified retrospective analysis of hospital registry data from a major health care network for patients undergoing surgery with general anesthesia from January 2007 to December 2015. The primary outcome was a composite of cardiac dysrhythmia, acute heart failure, transient ischemic attack, ischemic stroke, and acute myocardial infarction within 30 days after surgery. We performed sensitivity analyses in subgroups and propensity score adjustment and explored the association between exposure and outcome in subgroups of patients with high risk of cardiovascular complications., Results: Of the 98,147 cases receiving neuromuscular blockade, 73,181 (74.6%) received neostigmine and glycopyrrolate, while 24,966 (25.4%) did not. A total of 5612 patients (7.7%) in the anticholinesterase reversal group and 1651 (6.6%) in the control group (P < .001) experienced the primary outcome. After adjustment for clinical covariates, neostigmine and glycopyrrolate exposure was significantly associated in a dose-dependent fashion (P for trend <.001, respectively) with tachycardia (adjusted odds ratio = 2.1 [95% CI, 1.97-2.23]; P < .001) and bradycardia (adjusted odds ratio = 2.84 [95% CI, 2.49-3.24]; P < .001) but not with postoperative cardiovascular complications (adjusted odds ratio = 1.03 [95% CI, 0.97-1.1]; P = .33). We identified a significant effect modification of anticholinesterase reversal by high age, high-risk surgery, and history of atrial fibrillation (P for interaction = .002, .001, and .02, respectively). By using linear combinations of main effect and exposure-risk interaction terms, we detected significant associations between anticholinesterase reversal and cardiovascular complications toward a higher vulnerability in these patient subgroups., Conclusions: Neuromuscular blockade reversal with neostigmine and glycopyrrolate was associated with an increased incidence of intraoperative tachycardia and bradycardia but not with 30-day postoperative cardiovascular complications. Exploratory analyses suggest that a high postoperative cardiovascular complication risk profile may modify the effects of anticholinesterase reversal toward clinical relevance.
- Published
- 2020
- Full Text
- View/download PDF
47. Effect of acetylcholinesterase inhibitors on post-stroke cognitive impairment and vascular dementia: A meta-analysis.
- Author
-
Kim JO, Lee SJ, and Pyo JS
- Subjects
- Adult, Aged, Aged, 80 and over, Alzheimer Disease diagnosis, Cholinesterase Inhibitors adverse effects, Cholinesterase Inhibitors pharmacology, Female, Humans, Male, Mental Status and Dementia Tests, Middle Aged, Cholinesterase Inhibitors therapeutic use, Cognitive Dysfunction drug therapy, Cognitive Dysfunction etiology, Dementia, Vascular drug therapy, Dementia, Vascular etiology, Stroke complications
- Abstract
Cognitive impairment is a common complication observed after a stroke. Currently there are no definitively proven pharmacologic therapies for recovery from post-stroke cognitive impairment and vascular dementia. In this meta-analysis, we evaluated the efficacy and safety of cholinesterase inhibitors in their improvement of cognition in patients with post-stroke cognitive impairment and vascular dementia. We conducted a meta-analysis using seven eligible studies from 305 published articles. We investigated the differences in Mini-Mental State Examination (MMSE) and Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog) scores, before and after cholinergic augmentation in patients with post-stroke cognitive impairment and vascular dementia. MMSE and ADAS-cog scores were also compared during the subsequent follow-up periods. MMSE score of patients with post-stroke cognitive impairment was increased after cholinergic augmentation throughout the 24 weeks with mean differences [MD] of 3.000, 1.732, 1.578 1.516, and 1.222, at 4, 4-8, 8-12, 12-18, and 18-24 weeks, respectively. In addition, ADAS-cog scores decreased at 6, 12, 18, and 24 weeks by pharmaceutical augmentation, but not with placebo with mean differences [MD] of -2.333, -2.913, -2.767, -2.416, and -1.859, respectively. This meta-analysis shows that acetylcholinesterase inhibitors maintain a stable pattern of improved cognitive function in patients with post stroke cognitive impairment and vascular dementia without the increased risk of side effects., Competing Interests: The authors have declared that no competing interests exist.
- Published
- 2020
- Full Text
- View/download PDF
48. Differential blockade by huperzine A and donepezil of sympathetic nicotinic acetylcholine receptor-mediated nitrergic neurogenic dilations in porcine basilar arteries.
- Author
-
Shih CC, Chen PY, Chen MF, and Lee TJF
- Subjects
- Alkaloids administration & dosage, Alkaloids adverse effects, Alzheimer Disease drug therapy, Alzheimer Disease physiopathology, Animals, Basilar Artery drug effects, Basilar Artery innervation, Brain Stem blood supply, Brain Stem drug effects, Brain Stem pathology, Brain Stem physiopathology, Calcium metabolism, Cholinesterase Inhibitors administration & dosage, Cognitive Dysfunction physiopathology, Donepezil administration & dosage, Donepezil adverse effects, Dose-Response Relationship, Drug, Humans, Models, Animal, Nicotine metabolism, Nitrergic Neurons metabolism, Nitrergic Neurons physiology, Oocytes, Patch-Clamp Techniques, Rats, Receptors, Nicotinic metabolism, Sesquiterpenes administration & dosage, Sesquiterpenes adverse effects, Swine, Synaptic Transmission drug effects, Vasodilation physiology, Xenopus laevis, Basilar Artery physiopathology, Cholinesterase Inhibitors adverse effects, Cognitive Dysfunction chemically induced, Nitrergic Neurons drug effects, Vasodilation drug effects
- Abstract
Nicotinic acetylcholine receptor activation on the perivascular sympathetic nerves via axo-axonal interaction mechanism causes norepinephrine release, which triggers the neurogenic nitrergic relaxation in basilar arteries to meet the need of a brain. Donepezil and huperzine A, which are the cholinesterase inhibitors used for Alzheimer's disease therapy, exert controversial effects on nicotinic acetylcholine receptors. Therefore, we investigated how donepezil and huperzine A via the axo-axonal interaction regulate the neurogenic vasodilation of isolated porcine basilar arteries and define their action on different subtypes of the nicotinic acetylcholine receptor by using blood vessel myography, calcium imaging, and electrophysiological techniques. Both nicotine (100 μM) and transmural nerve stimulation (TNS, 8 Hz) induce NO-mediated dilation in the arteries. Nicotine-induced vasodilations were concentration-dependently inhibited by huperzine A and donepezil, with the former being 30 fold less potent than the latter. Both cholinesterase inhibitors weakly and equally decreased TNS-elicited nitrergic vasodilations. Neither huperzine A nor donepezil affected isoproterenol (a β adrenoceptor-agonist)- or sodium nitroprusside (a NO donor)-induced vasodilation. Further, huperzine A was less potent than donepezil in inhibiting nicotine-elicited calcium influxes in rodent superior cervical ganglionic neurons and inward currents in α7- and α3β2-nicotinic acetylcholine receptor-expressing Xenopus oocytes. In conclusion, huperzine A may exert less harmful effect over donepezil on maintaining brainstem circulation and on the nicotinic acetylcholine receptor-associated cognition deficits during treatment for Alzheimer's disease., (Copyright © 2019 Elsevier B.V. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
49. Evaluation of the Potential Acetylcholinesterase Inhibitor-Induced Rhinorrhea Prescribing Cascade.
- Author
-
Vouri SM, Possinger MC, Usmani S, Solberg LM, and Manini T
- Subjects
- Aged, Cholinesterase Inhibitors administration & dosage, Cross-Sectional Studies, Humans, Middle Aged, Cerebrospinal Fluid Rhinorrhea chemically induced, Cholinesterase Inhibitors adverse effects, Dementia drug therapy
- Published
- 2020
- Full Text
- View/download PDF
50. Comparison of incidence of anaphylaxis between sugammadex and neostigmine: a retrospective multicentre observational study.
- Author
-
Orihara M, Takazawa T, Horiuchi T, Sakamoto S, Nagumo K, Tomita Y, Tomioka A, Yoshida N, Yokohama A, and Saito S
- Subjects
- Adolescent, Adult, Aged, Female, Humans, Incidence, Japan, Male, Middle Aged, Retrospective Studies, Young Adult, Anaphylaxis chemically induced, Cholinesterase Inhibitors adverse effects, Neostigmine adverse effects, Sugammadex adverse effects
- Abstract
Background: Although cases of anaphylaxis caused by sugammadex have been reported, its incidence remains uncertain. Conversely, no studies have evaluated the incidence of anaphylaxis to neostigmine., Methods: This was a retrospective multicentre observational study of patients who underwent surgery under general anaesthesia between 2012 and 2016 to compare the incidence of anaphylaxis with sugammadex with that of neostigmine at four tertiary hospitals in Japan. To ensure the quality of diagnosis, only cases with a clinical history suggestive of anaphylaxis, along with positive results from in vitro or in vivo testing, were assessed., Results: From a total of 49 532 patients who received general anaesthesia included in this study, 18 cases of anaphylaxis were reported, of which six were attributable to sugammadex and none to neostigmine. There were no fatalities attributable to anaphylaxis. The incidence of anaphylaxis caused by all drugs or by sugammadex was calculated as 0.036% (95% confidence interval [CI]: 0.022-0.057%) and 0.02% (of the number of sugammadex cases) (95% CI: 0.007-0.044%), respectively., Conclusions: The results suggest that neostigmine might be safer than sugammadex when assessing only the incidence of anaphylaxis. We believe that there is room for reconsideration of the choice of reversal agent for neuromuscular blocking agents by all anaesthetists., Clinical Trial Registration: UMIN000022365; UMIN000033561., (Copyright © 2019 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.